Aims Renin-angiotensin system (RAS) and natriuretic peptides system (NPS) perturbations
govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy …

Abstract Background Neprilysin inhibitors (NEPi) are assisting the renin-angiotensin system
(RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a …

Alteration in renin‐angiotensin system (RAS) has been implicated in the pathophysiology of
diabetic kidney disease (DKD). The deleterious actions of angiotensin II (Ang II) could be …

Diabetic kidney disease (DKD) is one of the main causes of end-stage renal disease
(ESRD) and all-cause mortality in diabetic patients, despite the extensive use of angiotensin …

Diabetes is an enormous and ever-growing calamity and a global public health threat of the
21st century. Besides insulin and oral hypoglycaemic drugs, blockage of the renin …

Objective Diabetic nephropathy (DN) is characterized by glomerular and tubulointerstitial
injury, proteinuria and remodeling. Here we examined whether the combination of an …

Background: The need for an improved treatment for diabetic nephropathy is greatest in
patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This …

Objectives: Combined angiotensin receptor--neprilysin inhibition (ARNI) reduces
glomerulosclerosis better than single angiotensin receptor blockade (ARB) in diabetic …

Background: Natriuretic peptide system (NPS) alterations are involved in pathogenesis of
diabetic cardiomyopathy (DCM) and nephropathy (DN), however its epigenetic regulation is …

Diabetic nephropathy (DN) remains the most common cause of end-stage renal disease.
Although, adenosine acts as a local modulator with a cytoprotective function, extracellular …